Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues
Total Revenue	$ 40,519,800	$ 13,982,177
Operating expenses
General and administrative	12,197,111	11,477,701
Research and development	9,079,351	8,478,817
Sales and marketing	611,571	0
Royalty expenses	7,720,280	1,491,099
License fees	0	13,725,000
Total operating expenses	29,608,313	35,172,617
Income (loss) from operations	10,911,487	(21,190,440)
Other income (expense)
Interest income, net	437,653	144,696
Gain (loss) on debt settlement	16,503	(49,983)
Gain (loss) on foreign exchange	50,172	(48,306)
Total other income	504,328	46,407
Income (loss) before income taxes	11,415,815	(21,144,033)
Income tax (expense) benefit	177,235	(51,283)
Net income (loss)	$ 11,593,050	$ (21,195,316)
Income (loss) per share of common stock:
Basic (in dollars per share)	$ 2.88	$ (7.10)
Diluted (in dollars per share)	$ 2.17	$ (7.10)
Weighted average common stock outstanding
Basic (in shares)	4,018,464	2,985,335
Diluted (in shares)	5,342,378	2,985,335
Royalty and licensing revenue
Revenues
Total Revenue	$ 37,592,401	$ 13,262,321
Treatment investment revenue
Revenues
Total Revenue	643,955	250,549
Grant and contract revenue
Revenues
Total Revenue	$ 2,283,444	$ 469,307